HK1051965A1 - Use of il-18 inhibitors - Google Patents

Use of il-18 inhibitors

Info

Publication number: HK1051965A1
Authority: HK; Hong Kong
Prior art keywords: inhibitors; medicament; prevention; preparation; treatment
Prior art date: 2000-02-21

Application number

HK03104196A

Other languages

English (en)

Inventor

Yolande Chvatchko

Charles Dinarello

Christine Plater-Zyberk

Sander Van Deventer

Menachem Rubinstein

Daniela Novick

Soo-Hyun Kim

Original Assignee

Applied Research Systems

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-21

Filing date

2003-06-12

Publication date

2003-08-29

2003-06-12 Application filed by Applied Research Systems, Yeda Res & Dev filed Critical Applied Research Systems

2003-08-29 Publication of HK1051965A1 publication Critical patent/HK1051965A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

HK03104196A 2000-02-21 2003-06-12 Use of il-18 inhibitors HK1051965A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP00103590		2000-02-21
EP00103597		2000-02-21
EP00121651		2000-10-04
EP00125633		2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en)	2000-02-21	2001-02-20	Use of il-18 inhibitors

Publications (1)

Publication Number	Publication Date
HK1051965A1 true HK1051965A1 (en)	2003-08-29

Family

ID=27439934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK03104196A HK1051965A1 (en)	2000-02-21	2003-06-12	Use of il-18 inhibitors

Country Status (31)

Country	Link
US (1)	US20030157094A1 (da)
EP (1)	EP1257292B1 (da)
JP (1)	JP4744763B2 (da)
KR (3)	KR20070057282A (da)
CN (1)	CN1322897C (da)
AT (1)	ATE506959T1 (da)
AU (2)	AU2001240636B8 (da)
BG (1)	BG66134B1 (da)
BR (1)	BR0108514A (da)
CA (2)	CA2399298C (da)
CY (1)	CY1111687T1 (da)
CZ (1)	CZ304485B6 (da)
DE (1)	DE60144514D1 (da)
DK (1)	DK1257292T3 (da)
EA (1)	EA005583B1 (da)
EE (1)	EE05423B1 (da)
HK (1)	HK1051965A1 (da)
HR (1)	HRP20020652A2 (da)
HU (1)	HU227752B1 (da)
IL (2)	IL151388A0 (da)
ME (1)	ME00546B (da)
MX (1)	MXPA02008079A (da)
NO (1)	NO331971B1 (da)
NZ (3)	NZ546294A (da)
PL (1)	PL206549B1 (da)
PT (1)	PT1257292E (da)
RS (1)	RS51737B (da)
SI (1)	SI1257292T1 (da)
SK (1)	SK288032B6 (da)
TR (2)	TR200502508T2 (da)
WO (1)	WO2001062285A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001236807A1 (en) *	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) *	2000-02-21	2007-06-04	어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.	Ｉｌ-18 저해물질의 용도
US6894155B2 (en)	2000-10-11	2005-05-17	Viron Therapeutics	Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en)	2000-12-04	2010-05-18	Viron Therapeutics Inc.	Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) *	2001-05-16	2005-08-16	Yeda Res & Dev	Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
MXPA04002565A (es) *	2001-11-30	2004-05-31	Pfizer Prod Inc	Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
WO2004064713A2 (en) *	2003-01-20	2004-08-05	Vib Vzw	The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
JP4134166B2 (ja) *	2003-04-30	2008-08-13	独立行政法人科学技術振興機構	ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
CA2545733A1 (en) *	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
NZ552908A (en)	2004-06-30	2009-11-27	Atsuo Sekiyama	Indicator agent for noninflammatory stress response and use thereof
DK1808446T3 (da) *	2004-07-16	2012-05-14	Atsuo Sekiyama	IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SI2267024T1 (sl)	2005-06-03	2012-09-28	Ares Trading Sa	Proizvodnja rekombinantnega IL-18 vezavnega proteina
ES2375831T3 (es)	2005-06-10	2012-03-06	Ares Trading S.A.	Procedimiento para la purificación de prote�?nas de unión a il-18.
EP1746167A1 (en) *	2005-07-20	2007-01-24	Apoxis SA	Method for the identification of compounds susceptible to inhibit inflammation
ES2514495T3 (es)	2006-05-25	2014-10-28	Glaxo Group Limited	Anticuerpos humanizados modificados anti-interleucina-18
US8440195B2 (en) *	2010-11-12	2013-05-14	National University Corporation Chiba University	Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) *	2012-08-06	2012-09-19	Isis Innovation	Prevention and treatment of osteoarthritis
KR102512797B1 (ko) *	2013-09-05	2023-03-22	에이비2 바이오 에스에이	염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
CN107660150B (zh)	2015-03-05	2023-10-24	Ab2生物股份有限公司	Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN106109497A (zh) *	2016-07-25	2016-11-16	深圳爱生再生医学科技有限公司	治疗肝硬化的干细胞制剂
CN106834449B (zh) *	2017-01-10	2019-04-30	东南大学	与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN112236453A (zh) *	2018-06-14	2021-01-15	波尔多大学	使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎
JPWO2023286694A1 (da)	2021-07-13	2023-01-19
CN117647645B (zh) *	2024-01-29	2024-04-12	中国人民解放军总医院第一医学中心	Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985863A (en) *	1996-09-12	1999-11-16	Vertex Pharmaceuticals, Inc.	Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5744451A (en) *	1995-09-12	1998-04-28	Warner-Lambert Company	N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) *	1996-11-15	2003-12-17	Kennedy Institute Of Rheumatology	SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) *	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
JP4026923B2 (ja) *	1997-03-12	2007-12-26	株式会社林原生物化学研究所	ポリペプチド
US6087116A (en) *	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) *	1998-09-01	2002-01-09	Hayashibara Biochem Lab	INTERLEUKIN 18 BINDING PROTEIN
AR022952A1 (es) *	1999-03-19	2002-09-04	Smithkline Beecham Corp	ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU2001236807A1 (en) *	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) *	2000-02-21	2007-06-04	어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.	Ｉｌ-18 저해물질의 용도
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders

2001
- 2001-02-20 KR KR1020077010853A patent/KR20070057282A/ko not_active Application Discontinuation
- 2001-02-20 AT AT01911662T patent/ATE506959T1/de active
- 2001-02-20 MX MXPA02008079A patent/MXPA02008079A/es active IP Right Grant
- 2001-02-20 EE EEP200200463A patent/EE05423B1/xx unknown
- 2001-02-20 SI SI200130994T patent/SI1257292T1/sl unknown
- 2001-02-20 IL IL15138801A patent/IL151388A0/xx unknown
- 2001-02-20 EP EP01911662A patent/EP1257292B1/en not_active Expired - Lifetime
- 2001-02-20 ME MEP-2008-639A patent/ME00546B/me unknown
- 2001-02-20 DK DK01911662.3T patent/DK1257292T3/da active
- 2001-02-20 NZ NZ546294A patent/NZ546294A/en not_active IP Right Cessation
- 2001-02-20 US US10/204,387 patent/US20030157094A1/en not_active Abandoned
- 2001-02-20 BR BR0108514-0A patent/BR0108514A/pt not_active Application Discontinuation
- 2001-02-20 CA CA2399298A patent/CA2399298C/en not_active Expired - Lifetime
- 2001-02-20 JP JP2001561349A patent/JP4744763B2/ja not_active Expired - Lifetime
- 2001-02-20 HU HU0300061A patent/HU227752B1/hu unknown
- 2001-02-20 DE DE60144514T patent/DE60144514D1/de not_active Expired - Lifetime
- 2001-02-20 PL PL357554A patent/PL206549B1/pl unknown
- 2001-02-20 KR KR1020027010645A patent/KR20020086540A/ko not_active Application Discontinuation
- 2001-02-20 TR TR2005/02508T patent/TR200502508T2/xx unknown
- 2001-02-20 AU AU2001240636A patent/AU2001240636B8/en not_active Expired
- 2001-02-20 PT PT01911662T patent/PT1257292E/pt unknown
- 2001-02-20 EA EA200200890A patent/EA005583B1/ru not_active IP Right Cessation
- 2001-02-20 CN CNB018052932A patent/CN1322897C/zh not_active Expired - Lifetime
- 2001-02-20 NZ NZ520122A patent/NZ520122A/en not_active IP Right Cessation
- 2001-02-20 RS YU60402A patent/RS51737B/sr unknown
- 2001-02-20 AU AU4063601A patent/AU4063601A/xx active Pending
- 2001-02-20 SK SK1208-2002A patent/SK288032B6/sk not_active IP Right Cessation
- 2001-02-20 CZ CZ2002-2843A patent/CZ304485B6/cs not_active IP Right Cessation
- 2001-02-20 TR TR2002/02030T patent/TR200202030T2/xx unknown
- 2001-02-20 WO PCT/EP2001/001867 patent/WO2001062285A1/en active IP Right Grant
- 2001-02-20 NZ NZ535299A patent/NZ535299A/en not_active IP Right Cessation
- 2001-02-20 CA CA2683009A patent/CA2683009C/en not_active Expired - Lifetime
- 2001-02-20 KR KR1020077018043A patent/KR20070087256A/ko not_active Application Discontinuation
2002
- 2002-08-01 HR HRP20020652 patent/HRP20020652A2/hr not_active Application Discontinuation
- 2002-08-20 BG BG107018A patent/BG66134B1/bg unknown
- 2002-08-20 NO NO20023962A patent/NO331971B1/no not_active IP Right Cessation
- 2002-08-21 IL IL151388A patent/IL151388A/en active IP Right Grant
2003
- 2003-06-12 HK HK03104196A patent/HK1051965A1/xx unknown
2011
- 2011-07-13 CY CY20111100682T patent/CY1111687T1/el unknown

Also Published As

Publication number	Publication date
AU4063601A (en)	2001-09-03
CA2399298C (en)	2014-04-15
NO331971B1 (no)	2012-05-14
HRP20020652A2 (en)	2004-12-31
DK1257292T3 (da)	2011-07-18
KR20070087256A (ko)	2007-08-27
KR20020086540A (ko)	2002-11-18
YU60402A (sh)	2005-09-19
NZ546294A (en)	2008-02-29
EE200200463A (et)	2003-12-15
CZ304485B6 (cs)	2014-05-28
PL357554A1 (en)	2004-07-26
AU2001240636B2 (en)	2005-10-13
BR0108514A (pt)	2002-12-17
SK12082002A3 (sk)	2003-05-02
BG107018A (bg)	2003-09-30
JP2003523403A (ja)	2003-08-05
CN1322897C (zh)	2007-06-27
KR20070057282A (ko)	2007-06-04
DE60144514D1 (de)	2011-06-09
HUP0300061A3 (en)	2005-09-28
TR200502508T2 (tr)	2007-04-24
RS51737B (sr)	2011-10-31
HU227752B1 (en)	2012-02-28
US20030157094A1 (en)	2003-08-21
CN1404400A (zh)	2003-03-19
CA2683009A1 (en)	2001-08-30
BG66134B1 (bg)	2011-06-30
TR200202030T2 (tr)	2003-01-21
EE05423B1 (et)	2011-06-15
CY1111687T1 (el)	2015-10-07
IL151388A0 (en)	2003-04-10
EA005583B1 (ru)	2005-04-28
EA200200890A1 (ru)	2003-02-27
SK288032B6 (sk)	2012-12-03
NO20023962L (no)	2002-08-20
EP1257292A1 (en)	2002-11-20
IL151388A (en)	2009-09-01
EP1257292B1 (en)	2011-04-27
AU2001240636B8 (en)	2005-11-03
ME00546B (me)	2011-10-10
JP4744763B2 (ja)	2011-08-10
NZ535299A (en)	2006-06-30
HUP0300061A2 (hu)	2003-04-28
CZ20022843A3 (cs)	2003-02-12
PT1257292E (pt)	2011-07-05
CA2399298A1 (en)	2001-08-30
WO2001062285A1 (en)	2001-08-30
SI1257292T1 (sl)	2011-08-31
CA2683009C (en)	2014-09-23
ATE506959T1 (de)	2011-05-15
NO20023962D0 (no)	2002-08-20
MXPA02008079A (es)	2003-02-27
NZ520122A (en)	2005-04-29
PL206549B1 (pl)	2010-08-31

Publication	Publication Date	Title
IL151388A (en)	2009-09-01	Use of il-18 inhibitors
HRP20130602T1 (en)	2013-07-31	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
IL158088A0 (en)	2004-03-28	Remedies for inflammatory bowel diseases
GB0025173D0 (en)	2000-11-29	Therapeutic agents
GB0223040D0 (en)	2002-11-13	Therapeutic compounds
HK1089376A1 (en)	2006-12-01	Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
ZA200110504B (en)	2002-09-25	Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
IL158181A0 (en)	2004-03-28	N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2001035950A3 (en)	2001-11-29	Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2004105737A3 (en)	2005-06-09	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MXPA03003741A (es)	2003-07-28	Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
YU57803A (sh)	2006-05-25	Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
GB0020504D0 (en)	2000-10-11	Therapeutic method
EP1116488A3 (en)	2002-05-15	Treatment of inflammatory Bowel disease
AU8906201A (en)	2002-03-26	Methods and compositions for the treatment and prevention of sexual dysfunction
TR200502061T2 (tr)	2005-08-22	IL-18 inhibitörlerinin kullanımı.
MX2009004196A (es)	2009-06-30	Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.
AU2001295839A1 (en)	2002-05-15	Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
HUP0300083A3 (en)	2004-07-28	Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
SI1656372T1 (sl)	2013-08-30	Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni
EP1194162A4 (en)	2005-08-03	COMPOSITIONS AND METHODS OF PREVENTING, TREATING AND DETECTING TUBERHULOSIS AND OTHER DISEASES